Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System
VANCOUVER, BC. June 18, 2018 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”
or the “Company”), is pleased to announce the first four cataract procedures in Canada using the Zepto ® Capsulotomy
System (“Zepto”), a precision pulse capsulotomy device, have been successfully completed this week by Dr. Ike Ahmed at the Kensington Eye Institute
in Toronto, Ontario. Dr. Ike Ahmed is world-renowned for his skills in the diagnosis and surgical treatment of highly complex eye diseases. He is recognized
as being one of the most experienced complex eye surgeons in the world and has trained numerous surgeons in innovative surgical techniques.
“The creation of a consistent, circular, well-centered and sized capsulotomy for every patient is every cataract surgeon’s dream. Our first experience with Zepto was flawless with great intraoperative performance. We look forward to more experience and data in our evaluation of this promising technology,” said Dr. Ike Ahmed.
“We are absolutely delighted with the introduction of Zepto in Canada at a leading centre for cataract procedures in Canada, and thank Dr Ahmed and his team for their remarkable enthusiasm,” said Doug Janzen, CEO and Chairman of Aequus Pharmaceuticals. “All four cases were performed with great outcomes: perfect capsulorhexis’ within the expected timeframe. We look forward to our continued introduction of Zepto to surgeons across Canada.”
About Zepto Precision Pulse Capsulotomy System
The Zepto capsulotomy system provides consistent, high quality anterior lens capsulotomies during cataract surgery in a convenient, cost-effective, disposable
format. One of the key features is a collapsible super-elastic nitinol capsulotomy ring element with micron scale elements to create the unique and
strong Zepto capsulotomy edge. It also has a clear silicone suction cup to enable suction and generate Zepto’s proprietary capsulotomy action and to
allow Zepto capsulotomies on the patient’s individual visual axis.The AMA has recently given a category III code in the US as they see the distinctive
application and benefit of aligning on the patient’s own visual axis.
Zepto integrates seamlessly into the routine steps of cataract surgery with phacoemulsification. The surgeon does not need to alter his or her normal routine.
Instead of capsulorrhexis forceps or a cystitome, the surgeon simply reaches for Zepto.
The Zepto Capsulotomy System consists of a disposable Zepto capsulotomy handpiece that is attached to a small control console. Zepto uses the precision
pulse capsulotomy method, a proprietary combination of calibrated suction and a 4-millisecond multipulse energy algorithm to produce highly accurate
capsulotomies. Zepto’s unique single use hand piece can be inserted through incisions as small as 2.2mm, to create a perfectly circular and precisely
placed capsulotomy that can be centred on the visual axis. Zepto is ideal for surgery using premium lenses as well as difficult cases and creates a
capsulotomy with an edge strength greater than conventional methods or femtosecond lasers.For more information, please visit https://www.zeptocapsulotomy.ca.
About Aequus Pharmaceuticals, Inc.
Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality,
differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage
pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement
to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need
for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in
Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach
of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either
created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information,
please visit www.aequuspharma.ca
This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, the implementation of our business model and strategic plans, Aequus’ sales and marketing efforts. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: the success of Aequus’ sales and marketing efforts, general business and economic conditions, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.
Zepto ® is a registered trademark of Mynosys Cellular Devices.
Aequus Investor Relations
Aequus Investor Relations